SKŘIČKOVÁ, Jana, Lenka BABIČKOVÁ, Jana KAPLANOVÁ, Olga KUBOVÁ, Ivana PALKOVA a Marcela TOMÍŠKOVÁ. Results of treatment with gefitinib ("Iressa",ZD1839) in 45 patients with advanced non-small-cell lung cancer. In Woorkbook of Iressa Clinical Experience Meeting. Madrid, Spain: AstraZeneca, 2003, s. 58. |
Další formáty:
BibTeX
LaTeX
RIS
@inproceedings{488054, author = {Skřičková, Jana and Babičková, Lenka and Kaplanová, Jana and Kubová, Olga and Palkova, Ivana and Tomíšková, Marcela}, address = {Madrid, Spain}, booktitle = {Woorkbook of Iressa Clinical Experience Meeting}, keywords = {non-small-cell lung cancer; gefitinib treatment; survival rate}, language = {eng}, location = {Madrid, Spain}, pages = {58-58}, publisher = {AstraZeneca}, title = {Results of treatment with gefitinib ("Iressa",ZD1839) in 45 patients with advanced non-small-cell lung cancer}, year = {2003} }
TY - JOUR ID - 488054 AU - Skřičková, Jana - Babičková, Lenka - Kaplanová, Jana - Kubová, Olga - Palkova, Ivana - Tomíšková, Marcela PY - 2003 TI - Results of treatment with gefitinib ("Iressa",ZD1839) in 45 patients with advanced non-small-cell lung cancer PB - AstraZeneca CY - Madrid, Spain KW - non-small-cell lung cancer KW - gefitinib treatment KW - survival rate N2 - Forty-five patients with non-small-cell lung cancer underwent treatment with gefitinib; 51% of them had prior radiotherapy. Treatment duration was 1 to 14 months (median, 3 months). Diseased progressed in 18 patients within 3 months, but stabilised in 27 patients for longer than 3 months. Disease-related symptoms were generally milder after gefitinib treatment. ER -
SKŘIČKOVÁ, Jana, Lenka BABIČKOVÁ, Jana KAPLANOVÁ, Olga KUBOVÁ, Ivana PALKOVA a Marcela TOMÍŠKOVÁ. Results of treatment with gefitinib (''Iressa'',ZD1839) in 45 patients with advanced non-small-cell lung cancer. In \textit{Woorkbook of Iressa Clinical Experience Meeting}. Madrid, Spain: AstraZeneca, 2003, s.~58.
|